BidaskClub cut shares of PRA Health Sciences (NASDAQ:PRAH) from a strong-buy rating to a buy rating in a research note released on Friday.

Several other analysts have also weighed in on PRAH. Barclays increased their price target on PRA Health Sciences from $100.00 to $115.00 and gave the company an overweight rating in a report on Thursday, August 2nd. SunTrust Banks increased their price target on PRA Health Sciences from $100.00 to $110.00 and gave the company a buy rating in a report on Friday, August 3rd. Mizuho set a $100.00 price target on PRA Health Sciences and gave the company a hold rating in a report on Monday, August 6th. Credit Suisse Group increased their price target on PRA Health Sciences from $104.00 to $107.00 and gave the company an outperform rating in a report on Thursday, August 2nd. Finally, Jefferies Financial Group restated a buy rating and set a $115.00 price target on shares of PRA Health Sciences in a report on Friday, July 20th. Two analysts have rated the stock with a hold rating and ten have given a buy rating to the company. PRA Health Sciences has a consensus rating of Buy and an average price target of $111.50.

NASDAQ:PRAH opened at $96.61 on Friday. PRA Health Sciences has a fifty-two week low of $79.00 and a fifty-two week high of $112.88. The firm has a market cap of $6.54 billion, a P/E ratio of 30.19, a P/E/G ratio of 1.46 and a beta of 0.73. The company has a debt-to-equity ratio of 1.22, a quick ratio of 0.89 and a current ratio of 0.89.

PRA Health Sciences (NASDAQ:PRAH) last released its quarterly earnings results on Wednesday, October 31st. The medical research company reported $1.13 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $1.07 by $0.06. PRA Health Sciences had a return on equity of 25.75% and a net margin of 2.37%. The company had revenue of $717.60 million for the quarter, compared to analyst estimates of $729.63 million. During the same quarter in the prior year, the firm posted $0.88 EPS. PRA Health Sciences’s quarterly revenue was up 23.3% compared to the same quarter last year. Sell-side analysts forecast that PRA Health Sciences will post 3.93 EPS for the current year.

A number of institutional investors have recently made changes to their positions in the business. State of Alaska Department of Revenue acquired a new position in shares of PRA Health Sciences during the second quarter valued at about $572,000. Fox Run Management L.L.C. acquired a new position in shares of PRA Health Sciences during the second quarter valued at about $201,000. Retirement Systems of Alabama acquired a new position in shares of PRA Health Sciences during the second quarter valued at about $6,120,000. Oakbrook Investments LLC acquired a new position in shares of PRA Health Sciences during the second quarter valued at about $247,000. Finally, Louisiana State Employees Retirement System acquired a new position in shares of PRA Health Sciences during the second quarter valued at about $1,279,000.

About PRA Health Sciences

PRA Health Sciences, Inc, a contract research organization, provides outsourced clinical development services to the biotechnology and pharmaceutical industries worldwide. The company operates in two segments, Clinical Research and Data Solutions. The Clinical Research segment offers product registration services, including clinical trial management, project management, regulatory affairs, therapeutic expertise, clinical operations, data and programming, safety and risk management, biostatistics and medical writing, quality assurance, and late phase services.

Featured Article: Market Capitalization, Large-Caps, Mid-Caps, Small-Caps

Analyst Recommendations for PRA Health Sciences (NASDAQ:PRAH)

Receive News & Ratings for PRA Health Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PRA Health Sciences and related companies with MarketBeat.com's FREE daily email newsletter.